Maze Therapeutics (NASDAQ:MAZE) CMO Harold Bernstein Sells 15,000 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $26.22, for a total value of $393,300.00. Following the sale, the chief marketing officer owned 15,000 shares of the company’s stock, valued at $393,300. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Wednesday, April 1st, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $29.46, for a total value of $441,900.00.
• On Friday, March 20th, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $49.10, for a total value of $736,500.00.
• On Tuesday, March 10th, Harold Bernstein sold 30,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $50.45, for a total value of $1,513,500.00.

Maze Therapeutics Price Performance

Shares of MAZE traded down $1.06 during trading hours on Monday, hitting $24.50. 596,266 shares of the stock were exchanged, compared to its average volume of 727,496. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88. Maze Therapeutics, Inc. has a 12-month low of $9.15 and a 12-month high of $53.65. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -9.68 and a beta of 2.50. The stock’s 50-day moving average price is $33.41 and its two-hundred day moving average price is $37.97.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The business had revenue of $20.00 million during the quarter. Research analysts expect that Maze Therapeutics, Inc. will post -2.63 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MAZE has been the topic of a number of recent research reports. BTIG Research reissued a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a research note on Wednesday, March 25th. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. HC Wainwright boosted their price objective on Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. Guggenheim boosted their price objective on Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Finally, Truist Financial lowered their price objective on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, April 14th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $66.00.

Hedge Funds Weigh In On Maze Therapeutics

Large investors have recently modified their holdings of the business. Royal Bank of Canada raised its holdings in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after buying an additional 363 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of Maze Therapeutics in the 4th quarter valued at $39,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Maze Therapeutics in the 4th quarter valued at $43,000. California State Teachers Retirement System raised its holdings in shares of Maze Therapeutics by 138.0% in the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after buying an additional 766 shares during the period. Finally, Ameritas Investment Partners Inc. raised its holdings in shares of Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares during the period.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.